How to Prevent Heart Disease: The 8 Levers That Actually Move the Numbers
Heart disease is the leading cause of death on Earth, and most of the people it kills early did not have to die early. The World Health Organization puts the share of premature heart disease and stroke that is preventable at roughly 80%. The INTERHEART study, which compared about 15,000 first-heart-attack patients with 15,000 matched controls across 52 countries, found that nine ordinary, modifiable risk factors accounted for about 90% of the population-level risk of a first heart attack — everywhere, in every ethnic group, in men and women, young and old.
That is an unusual thing to be able to say about a disease. It means the heart attack at 58 is not mostly bad luck or bad genes. It is mostly the arithmetic of a few numbers, compounded over decades. The good news buried inside that grim fact is that the numbers are measurable, most of them are controllable, and the interventions are well studied.
This post walks through the eight levers with the strongest evidence, in roughly the order of how much they matter. I've pulled the figures from the primary trials and meta-analyses rather than from summaries, because a version of this article circulates online with a lot of confident numbers attached — and when I checked them, several were wrong or attached to the wrong study. I'll flag those as we go, since the corrections are useful in their own right.
First, What Actually Causes It
Atherosclerosis — the disease behind most heart attacks and ischemic strokes — is not "clogged pipes" and it is not an inevitable feature of aging. It is a slow inflammatory process that starts when certain cholesterol-carrying particles in the blood get trapped in the wall of an artery, become oxidized, and attract immune cells that turn into the fatty, scarred deposits we call plaque. The process begins in childhood. A heart attack in your fifties is the end of a story that started forty years earlier.
The particles that do the trapping all share one feature: a surface protein called apolipoprotein B, or ApoB. Every LDL particle, every VLDL and IDL particle, and every lipoprotein(a) particle carries exactly one ApoB molecule. So an ApoB blood test is literally a count of the particles capable of lodging in your artery walls. Standard LDL cholesterol (LDL-C) measures something adjacent — the mass of cholesterol those particles carry — and most of the time the two track together. When they diverge, which happens often in people with insulin resistance, high triglycerides, or metabolic syndrome, it is the particle count that predicts events. A 2019 review in JAMA Cardiology laid out the case that ApoB is the more accurate measure of atherogenic risk; the 2026 ACC/AHA cholesterol guideline now says ApoB "may be used to assess any residual risk" in exactly those groups.
The single most important idea in cardiovascular prevention: the risk of a heart attack is a function of how many ApoB particles are in your blood multiplied by how many years they've been there. Lower the number, and start earlier, and the curve bends. Genetic studies of people born with lifelong low LDL — who have strikingly low rates of heart disease with no apparent downside — are the cleanest evidence that this is causal, not just correlated.
Lever 1: Get Your ApoB (and LDL) Down, and Keep It Down
What's a good number? The European guidelines set ApoB targets by risk tier: under 100 mg/dL for moderate risk, under 80 for high risk, under 65 for very high risk. The new 2026 American guideline doesn't set ApoB thresholds but does set LDL-C goals — under 100 mg/dL for borderline or intermediate risk, under 70 for high risk, under 55 for people who already have cardiovascular disease. You'll see figures like "ApoB 60–80" quoted online as a universal target; that's the aggressive-prevention view, and there's a reasonable argument for it (there's no observed floor below which lowering ApoB stops helping), but it isn't a guideline recommendation for everyone, and your target should be set with your doctor based on your overall risk.
The tools, in rough order of power:
- Statins. The West of Scotland trial randomized 6,595 men with high cholesterol and no prior heart disease to pravastatin or placebo. Over about five years, coronary events fell 31% and death from any cause fell 22%. A meta-analysis of seven primary-prevention trials with nearly 43,000 participants found statins cut major coronary events by 29%, major cerebrovascular events by 14%, and revascularization procedures by 34%, with a mortality reduction (8%) that didn't reach statistical significance over the trials' short follow-up. Statins are among the most thoroughly tested drugs in the history of medicine. If your risk is high enough that your doctor recommends one, the evidence is squarely on their side.
- Ezetimibe, PCSK9 inhibitors, bempedoic acid. Add-ons or alternatives when statins aren't enough or aren't tolerated. Same mechanism — fewer ApoB particles — same direction of benefit.
- Diet. Replacing saturated fat with unsaturated fat, and adding soluble fiber, each lower LDL by a meaningful amount (more on both below). Diet alone typically moves LDL by 10–20%; for many people that's enough, and for many others it isn't, and there's no shame in either.
One number diet won't touch: lipoprotein(a), or Lp(a). It's a genetically determined ApoB particle that's especially sticky in artery walls, it's elevated in roughly one in five people, and lifestyle barely moves it. The 2026 guideline recommends every adult have it measured at least once in their life; a level at or above 50 mg/dL (125 nmol/L) carries about a 1.4-fold higher long-term risk of heart attack or stroke. Knowing it's high doesn't yet come with a specific drug (several are in late-stage trials), but it changes how aggressively everything else should be managed.
Lever 2: Blood Pressure
Pressure is mechanical stress on the inside of every artery, and sustained high pressure damages the thin endothelial lining that keeps ApoB particles out. The best-known modern trial here is SPRINT, and it's worth getting the details right because the online version of this article gets them wrong.
SPRINT enrolled 9,361 adults aged 50 and older with a systolic pressure of 130 or higher and elevated cardiovascular risk. People with diabetes or prior stroke were excluded. Half were treated to a systolic target below 120 mmHg, half to the standard target below 140. The trial was stopped early, after a little over three years, because the intensive group had 25% fewer major cardiovascular events and 27% fewer deaths from any cause. That's a striking result. But three qualifications matter: the trial set no diastolic target (so "below 120/80" is not what it tested); its blood pressure readings were taken with an automated cuff after five minutes of quiet rest, which reads several points lower than a typical clinic measurement; and the intensive group had more episodes of low blood pressure, fainting, electrolyte problems, and acute kidney injury. The right reading of SPRINT is "lower is better for most high-risk adults, with medical supervision" — not "everyone should chase 120/80 on their own."
What moves blood pressure without a prescription
- The DASH eating pattern (vegetables, fruit, whole grains, legumes, low-fat dairy, limited sodium) lowers systolic pressure by roughly 3–5 mmHg on average in trials, and by more in people who start with hypertension. That sounds small; at the population level a 5 mmHg drop is associated with roughly a 10% reduction in cardiovascular events.
- Potassium up, sodium down. Most of the DASH effect runs through this ratio. Leafy greens, beans, potatoes, squash, and yogurt on the potassium side; packaged and restaurant food is where the sodium hides.
- Aerobic exercise lowers resting systolic pressure by roughly 5–8 mmHg in people with hypertension, less in people who start normal.
- Weight loss, less alcohol, adequate sleep. Each has trial support in the same low-single-digit mmHg range, and they stack.
- Slow breathing. Device-guided slow breathing (around six breaths a minute) lowers blood pressure modestly in some trials, and there's early evidence for inspiratory muscle training. I'd file this under "helpful, not load-bearing." The "nasal breathing boosts nitric oxide and lowers blood pressure" claim you'll see online has a real mechanism behind it but no outcome data; if you want the breathing tool with the best evidence for calming the nervous system, it's the physiological sigh.
Lever 3: Metabolic Health
Type 2 diabetes roughly doubles cardiovascular risk, and the damage starts well before the diagnosis. Chronically high insulin and glucose stiffen arteries, degrade the protective gel layer (the glycocalyx) that lines them, shift LDL toward smaller, denser particles that penetrate artery walls more easily, and generate advanced glycation end-products that cross-link the proteins in vessel walls. Insulin resistance is also the main reason LDL-C and ApoB disagree — which is why ApoB matters most in exactly this group.
The targets are where the online version of this advice overreaches. The claim that you should keep HbA1c under 5.4% and fasting glucose under 90 mg/dL is not based on any outcome trial. The evidence-based cutoffs are HbA1c below 5.7% and fasting glucose below 100 mg/dL (the top of the normal range); prediabetes runs from 5.7 to 6.4% and 100 to 125 mg/dL. Is a 5.2 better than a 5.6? Observational data lean gently that way. But nobody has shown that driving a healthy person's A1c from 5.6 to 5.3 prevents anything, and chasing it can turn into an unhealthy relationship with a glucose monitor. Aim for the normal range, and pay more attention to the trend than the decimal.
What actually improves insulin sensitivity is unglamorous: losing visceral fat if you carry it, building and using muscle (next lever), sleeping enough, and eating mostly unrefined food with a lot of fiber. Which brings up the biggest error in the popular version of this story.
The seed-oil claim doesn't survive contact with the evidence. You'll read that "ultra-processed seed oils" should be eliminated alongside refined sugar. The processed-food part is sound. The oil part is backwards. A meta-analysis of eight randomized trials found that replacing saturated fat with polyunsaturated fat — which is mostly what seed oils are — reduced coronary events by 19%, about a 10% reduction for every 5% of calories swapped. A pooled analysis of 30 cohort studies found that people with higher blood levels of linoleic acid, the main fat in seed oils, had lower rates of cardiovascular disease and cardiovascular death. Deep-fried food in reused oil is a problem. A tablespoon of canola or sunflower oil in a salad dressing is not, and swapping it for butter or coconut oil raises your ApoB.
Lever 4: Cardiorespiratory Fitness
If you measure only one thing about a person's body and want to predict how long they'll live, measure their fitness. The Cleveland Clinic study I wrote about in the gym exercises post followed 122,007 people for a median of 8.4 years after a treadmill stress test. Compared with the fittest 2–3% ("elite"), people in the bottom quarter of fitness had five times the risk of dying (adjusted hazard ratio 5.04). The relationship was graded at every step, and there was no upper limit at which more fitness stopped helping.
Two things are worth knowing about that figure. It's observational — fit people differ from unfit people in ways that adjustment can't fully capture — so the "five-fold" is an association, not a guaranteed return on training. And you get most of the benefit early: going from the bottom quarter to merely below-average cut mortality risk by half in that data. The biggest gains go to the people who are currently doing the least.
For the training itself, the structure that the evidence supports is a base of moderate aerobic work (150 minutes or more per week of the pace where you can talk in full sentences but wouldn't want to) plus a smaller dose of hard intervals to push the ceiling. The best-studied interval protocol is the Norwegian 4x4 — four rounds of four minutes at 85–95% of maximum heart rate with three minutes of easy recovery — which in a 2007 trial raised VO2max by about 7% in eight weeks while work-matched moderate continuous training didn't move it at all. One interval session a week is enough for most people. Two if you're already fit. The details are in the gym post.
And it doesn't have to be a gym. A Spanish primary-care trial randomized 364 older adults to a nine-month program of two hours of supervised walking per week plus a monthly social gathering. Systolic blood pressure fell 6.6 mmHg, total cholesterol 10 mg/dL, and LDL 9 mg/dL. Two years later, 2.5% of the walking group had suffered a cardiovascular event versus 10.5% of the controls. It was a small trial with an unbalanced design, so hold the exact numbers loosely. The direction is not in doubt.
Lever 5: Muscle
Skeletal muscle is the largest disposal site for glucose in the body — it takes up most of the sugar from a meal — and the more of it you have and the more you use it, the less insulin your pancreas has to produce to clear the same load. That's the mechanism linking resistance training to the metabolic lever above. It also lowers resting blood pressure, reduces visceral fat, and preserves the strength that keeps people independent.
The dose is smaller than the fitness industry suggests. A 2022 meta-analysis in the British Journal of Sports Medicine found that 30 to 60 minutes of muscle-strengthening activity per week was associated with 10–17% lower risk of death, cardiovascular disease, and cancer. Combined with aerobic exercise, the mortality reduction was about 40%. Two sessions a week of compound movements — a squat or leg press, a hinge, a row, a press, a carry — is the floor, and it's a high-value floor.
Lever 6: What You Eat
Diet works on nearly every lever above at once, which is why the dietary trials show event reductions that look too large for any single mechanism.
The Mediterranean pattern: the best trial we have
PREDIMED randomized 7,447 Spanish adults at high cardiovascular risk to a Mediterranean diet supplemented with extra-virgin olive oil, the same diet supplemented with mixed nuts, or a control diet with advice to reduce fat. Over a median of 4.8 years, the olive-oil group had 31% fewer major cardiovascular events and the nut group 28% fewer. (A note for the skeptics: the original 2013 paper was retracted after problems with randomization at some sites were found; the 2018 re-analysis, which is the version I'm citing, excluded the affected participants and reached the same conclusion.) A 2023 meta-analysis of 16 cohort studies covering more than 722,000 women found that high adherence to a Mediterranean diet was associated with 24% lower cardiovascular disease and 23% lower mortality.
Fiber: the most underrated lever on this list
The 2019 Lancet series pooling 185 prospective studies and 58 clinical trials found that the highest fiber consumers had 15–30% lower all-cause and cardiovascular mortality than the lowest, and 16–24% lower incidence of coronary heart disease, stroke, and type 2 diabetes. Benefits were greatest at 25–29 grams per day, with evidence that more was better still. Most adults in the U.S. eat about 15. Soluble, viscous fiber — from oats, barley, beans, lentils, psyllium — has a specific extra trick: it binds bile acids in the gut, forcing the liver to pull cholesterol out of the blood to make more, which is the mechanism behind the LDL drop of about 0.25 mmol/L (roughly 10 mg/dL) seen with 3 grams a day of oat beta-glucan in a meta-analysis of randomized trials. The "40–50 grams a day" figure you'll see online has no trial behind it; 30-plus does, and it's a much more achievable place to start.
DASH: built for blood pressure, good for everything
A meta-analysis of 20 DASH trials found the diet lowered systolic pressure 5.2 mmHg, diastolic 2.6, total cholesterol 0.20 mmol/L, and LDL 0.10 mmol/L. Plugged into the Framingham equation, those changes predicted about a 13% reduction in 10-year cardiovascular risk. That's a model, not a measured outcome — but it's a model built on measured risk factors.
Notice what these three patterns have in common. Vegetables, fruit, legumes, whole grains, nuts, olive oil, fish. Little red and processed meat. Almost nothing from a package with more than a handful of ingredients. You don't need to pick a camp. The overlap is the diet.
Lever 7: Don't Smoke, and If You Do, Stop
Every inhaled puff of tobacco smoke delivers oxidants and particulates directly into the blood, and the effects on the arteries are immediate: the endothelium stops producing nitric oxide, platelets become stickier, and existing plaques become more prone to rupture. Smoking roughly doubles to triples cardiovascular risk. There is no dose that's safe, and "cutting down" delivers a fraction of the benefit of quitting.
The recovery timeline is real and quicker than most people think, though the popular "risk halves in a year" framing is optimistic. In the Framingham cohorts, heavy smokers who quit had a 39% lower risk of cardiovascular disease within five years compared with those who kept smoking. Risk kept falling with time and stopped being significantly higher than a never-smoker's roughly 10 to 15 years after quitting. Vaping is newer and the long-term data are thin; what exists shows acute effects on blood vessel function and blood pressure similar in direction to cigarettes, if smaller. If you vape to quit smoking, that's a reasonable bridge. If you vape instead of never having smoked, you're running an experiment on yourself.
Lever 8: Know Your Numbers Early
Everything above works better the earlier you start, because the disease is cumulative. Here's what the 2026 ACC/AHA guideline actually recommends — which is more measured than the "everyone in their 30s should get a calcium scan" advice circulating online.
| What | Who / when | Why |
|---|---|---|
| Lipid panel + ApoB | Every adult; ApoB especially if you have insulin resistance, high triglycerides, diabetes, or metabolic syndrome | The particle count that drives plaque |
| Lipoprotein(a) | Once in adulthood — it doesn't change | Genetic risk that lifestyle can't lower; changes how aggressive to be with everything else |
| Blood pressure | Every visit; a home cuff is worth owning | Clinic readings are noisy; home averages predict better |
| HbA1c + fasting glucose | Every 1–3 years from age 35, earlier if overweight or family history | Catches prediabetes a decade before diabetes |
| PREVENT risk calculator | Adults 30–79 without known heart disease | Converts your numbers into a 10-year risk that determines treatment intensity |
| Coronary artery calcium (CAC) scan | Men 40+ and women 45+ with borderline or intermediate risk, when the result would change the statin decision | Directly images plaque; a score of zero strongly lowers near-term risk, any score above zero argues for treatment |
| hs-CRP | Optional "risk enhancer" if your risk is borderline | Marker of vascular inflammation; useful as a tiebreaker, not a target |
Why not scan everyone at 35? Because calcium is a late feature of plaque. Young arteries can carry plenty of soft, non-calcified plaque and score zero, so a clean scan in your thirties is falsely reassuring while also delivering a dose of radiation. The lipid and metabolic numbers are what matter in your thirties. The scan earns its place a decade later, when it can tell a borderline-risk person whether they're actually on the path or not.
Claims You'll See Online That Don't Hold Up
Since this post exists partly because I fact-checked a popular version of it, here's the short list of things to be wary of when you read about heart disease prevention — including in posts that cite real studies, because citing a real study and citing it accurately are different things.
- "SPRINT proved everyone should be below 120/80." It tested systolic-only targets in high-risk adults over 50 without diabetes, with a measurement method that reads low, and found more side effects alongside the benefit.
- "Keep HbA1c under 5.4% and fasting glucose under 90." No outcome trial supports those cutoffs. Normal range is the evidence-based target.
- "Eliminate seed oils." Randomized trials and biomarker cohorts point the other way: replacing saturated fat with polyunsaturated fat reduces coronary events.
- "Excess heart attack risk drops 50% within one to two years of quitting." The best modern cohort data show about 39% lower CVD risk within five years, with full normalization taking 10–15 years. Still a spectacular return on quitting.
- "Everyone should get a calcium scan in their 30s or 40s." Guidelines say men 40+ and women 45+ at borderline-to-intermediate risk, when it would change a decision.
- "Eat 40–50 grams of fiber a day." The data show a large benefit reaching 25–29 grams with gains beyond that. Nobody has tested 50.
- Check the links. In the version I reviewed, three of six cited studies pointed to papers that didn't contain the numbers attributed to them — a German-language review standing in for the West of Scotland statin trial, a diabetes meta-analysis standing in for a women's heart disease meta-analysis, and so on. The numbers were real; the sources were shuffled. Here's how to check for yourself.
The Bottom Line
Heart disease is a slow accumulation of a few measurable insults to your arteries, and every one of them is on this list. Know your ApoB, your Lp(a), your blood pressure, and your A1c, and get them into range — with food and movement first, and with medication when the numbers or your risk call for it, because the medications work. Build the aerobic base and lift twice a week, because fitness and muscle are the two strongest predictors of a long life that you can actually train. Eat the diet that PREDIMED, DASH, and the fiber data all converge on. Don't smoke. And get screened on the schedule the evidence supports rather than the one that sells scans.
None of this is exotic, and that's the point. The people who don't die of heart disease at 60 mostly aren't doing anything remarkable. They're doing a handful of ordinary things, measured, for a long time.
This article is for educational purposes and isn't medical advice. Targets for cholesterol, blood pressure, and glucose depend on your personal risk profile and should be set with a clinician who knows your history — especially before starting, stopping, or changing any medication.
Key Sources
- Yusuf S, et al. Effect of potentially modifiable risk factors associated with myocardial infarction in 52 countries (the INTERHEART study). The Lancet, 2004. PubMed
- Ference BA, et al. Low-density lipoproteins cause atherosclerotic cardiovascular disease: evidence from genetic, epidemiologic, and clinical studies. EAS Consensus Panel. European Heart Journal, 2017. PubMed
- Sniderman AD, et al. Apolipoprotein B particles and cardiovascular disease: a narrative review. JAMA Cardiology, 2019. PubMed
- 2026 ACC/AHA Guideline for the Management of Dyslipidemia. Circulation / JACC, March 2026. ACC summary
- Shepherd J, et al. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia (WOSCOPS). New England Journal of Medicine, 1995. PubMed
- Thavendiranathan P, et al. Primary prevention of cardiovascular diseases with statin therapy: a meta-analysis of randomized controlled trials. Archives of Internal Medicine, 2006. PubMed
- SPRINT Research Group. A randomized trial of intensive versus standard blood-pressure control. New England Journal of Medicine, 2015. PubMed
- Filippou CD, et al. DASH diet and blood pressure reduction in adults with and without hypertension: a systematic review and meta-analysis of RCTs. Advances in Nutrition, 2020. PubMed
- Siervo M, et al. Effects of the DASH diet on cardiovascular risk factors: a systematic review and meta-analysis. British Journal of Nutrition, 2015. PubMed
- Mozaffarian D, Micha R, Wallace S. Effects on coronary heart disease of increasing polyunsaturated fat in place of saturated fat: a systematic review and meta-analysis of randomized controlled trials. PLoS Medicine, 2010. PubMed
- Mandsager K, et al. Association of cardiorespiratory fitness with long-term mortality among adults undergoing exercise treadmill testing. JAMA Network Open, 2018. PubMed
- Helgerud J, et al. Aerobic high-intensity intervals improve VO2max more than moderate training. Medicine & Science in Sports & Exercise, 2007. PubMed
- Arija V, et al. Effectiveness of a physical activity program on cardiovascular disease risk in adult primary health-care users: the "Pas-a-Pas" community intervention trial. BMC Public Health, 2017. PubMed
- Momma H, et al. Muscle-strengthening activities are associated with lower risk and mortality in major non-communicable diseases. British Journal of Sports Medicine, 2022. PubMed
- Estruch R, et al. Primary prevention of cardiovascular disease with a Mediterranean diet supplemented with extra-virgin olive oil or nuts (PREDIMED, corrected republication). New England Journal of Medicine, 2018. PubMed
- Pant A, et al. Primary prevention of cardiovascular disease in women with a Mediterranean diet: systematic review and meta-analysis. Heart, 2023. PubMed
- Reynolds A, et al. Carbohydrate quality and human health: a series of systematic reviews and meta-analyses. The Lancet, 2019. PubMed
- Whitehead A, et al. Cholesterol-lowering effects of oat β-glucan: a meta-analysis of randomized controlled trials. American Journal of Clinical Nutrition, 2014. PubMed
- Duncan MS, et al. Association of smoking cessation with subsequent risk of cardiovascular disease. JAMA, 2019. PubMed
Related Reading
- The Best Gym Exercises for a Longer Life — the full training program behind levers 4 and 5
- Why Real Food Is Medicine — the whole-food principles that PREDIMED and DASH share
- Fermentation, Gut Health, and Longevity — fiber's other job
- The Physiological Sigh — the breathing tool with the best evidence
- How to Read Health Science — how to check a claim's sources yourself
- The Science of Living Longer — where heart disease sits among the other longevity levers
Know Your Numbers
Get evidence-based wellness practices grounded in science — not biohacking hype — delivered weekly.
Subscribe to the Newsletter